Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection

Abstract

Surface Plasmon Resonance imaging (SPRi) was used to determine the presence and strength of binding of IgG, IgM and IgA against the Receptor Binding Domain (RBD) of SARS-CoV-2 in sera of 119 CoViD-19 patients. The high-throughput assay enables to follow the specific immune response of ultimate 384 individuals for these four parameters in one run. The measured IgG, IgM and IgA levels correlated with ELISA (Euroimmun: Anti-SARS-CoV-2, IgG assay, r-0.95, ECLIA: Anti-SARS-CoV-2 Ig electrochemiluminescence r=0.73). During the course of the disease, the IgG levels and strength of binding increased while generally the IgM and IgA levels went down. Recovered patients all show high strength of binding of the IgG type to the RBD protein. The anti-RBD immune globulins SPRi assay provides additional insights in the immune status of patients recovering from CoViD-19 and can be applied for the assessment of the immune reaction of healthy individuals in vaccination programmes.

Cross-Validation of ELISA and a Portable Surface Plasmon Resonance Instrument for IgG Antibodies Serology with SARS-CoV-2 Positive Individuals

“…SPR sensing is thus well suited for quantitative analysis of SARS-CoV-2 proteinprotein 35,36 or protein-antibody 37,38 interactions, detecting SARS-CoV-2 RNA 39,40 or sensing antibodies associated to SARS-CoV-2 41,42 . A recent study showed that the use of SPR imaging can be used to detect antibody isotypes in sera of clinical patients 43 , paving the way for the use of SPR in clinical investigations. That initial study focused on the detection of antibodies only for the spike protein on an instrument confined to a centralized laboratory.…”